Intellia Therapeutics

ARK Invest increased its position in Intellia Therapeutics by 89,284 shares worth about 1.09 million USD via the ETFs ARKK and ARKG. At the same time, ARK sold 4,156 shares of Brera Holdings for approximately 15,377 USD through ARKK, ARKW and ARKF. ARK also bought shares of the 3iQ Solana Staking ETF (4,021 shares, about 33,615 USD), reflecting a strategic focus on biotechnology and selective investments in crypto assets. » Mere på de.investing.com

The FDA has formally accepted the Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) and granted a priority review; the PDUFA date is March 10, 2027. A decision by an advisory committee is not currently planned, reducing regulatory uncertainty. The filing is based on strong Phase 3 data from the HAELO study showing a median reduction in monthly HAE attacks of 87% and 62% of patients attack-free over six months. Analysts reaffirmed a "Market Outperform" rating with a $30.00 price target, creating a near-term catalyst for the stock. » Mere på de.investing.com

Cathie Wood’s ARK bought 39,548 shares of Intellia Therapeutics on September 3 via the ARKG ETF for about $504,632, continuing a series of increases started in the days before. At the same time, ARK sold a total of 10,853 shares of Brera Holdings across several ETFs for roughly $41,241, further trimming the position in recent days. The transactions reflect a strategic reallocation in favor of Intellia and a reduction of exposure to Brera. » Mere på de.investing.com

Intellia presented phase‑3 data from the HAELO study showing lonvo‑z reduced the monthly rate of attacks requiring treatment between weeks 5 and 28 by 89% versus placebo (0.19 vs. 1.79). Moderate to severe attacks fell by 91% and quality of life improved substantially more than with placebo. Adverse events were mostly mild to moderate, and no serious events were reported in the treatment arm. Intellia has filed a rolling BLA with the FDA and expects approval and a U.S. launch in the first half of 2027, while the stock has recently fallen despite the data. » Mere på de.investing.com

The Intellia share dropped more than 8% in premarket trading to $12.09 after the company placed roughly 16.7 million shares at $10.75 each. The offering was increased from an initial $150 million to $180 million and was conducted at an 18.6% discount to the closing price. Proceeds are intended to finance clinical development, the commercialization of lead programs, R&D of additional candidates, and potential acquisitions. » Mere på de.investing.com